reference/31076028

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/31076028

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article
endingPage	e180
issn	2352-3026
issueIdentifier	4
pageRange	e170-e180
publicationName	The Lancet. Haematology
startingPage	e170
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_7a5c286bf13503f8a16213ef29cf03d0
bibliographicCitation	Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. The Lancet Haematology. 2018 Apr;5(4):e170–80. doi: 10.1016/s2352-3026(18)30030-9.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_33c01b1f11275d33cb864fb3ee64f56d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5baeaced258fcb8f229fd4eeae0dcb2e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_366509e3b963175ba944e1a562d09922 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ecb17c5f50aa55244ee678fce562d770 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7399eaac4ec5ef67bb6ac1e992cee572 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_19c76dcfc488cd2ed20bcf84f4b27192 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_df19071b23102355a6c78569bbe182f1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_942010b238f8b67b8e98d1eb60c00648 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fccb32894b60915f88fd6179d64e2f2d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0c71637cba40fbc8d17679e87de2d741 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c161c42f5c9383e20215988ca89926eb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f2cd456594dbb4ac72fa8e8c52d965df http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8cb6481399b806fd473134c884faa622 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_26c4c5574e5ca1ee491350cefcb356ca http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1de293d74b069d520aa56c52cd3e18eb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d90755af7f19adbf34786e1905824809 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_909f2f89c7a40b25b9bbfff8d2632bf1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6758b7227de60d1c1addbdbc78106ce5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4d5e96ff7b5e3364baa087513b199f5e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fe842df21a2fed6ac64719b95601e1b7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6079300414e0f95c13520776a85e39d9
date	201804
identifier	https://pubmed.ncbi.nlm.nih.gov/29550382 https://pubmed.ncbi.nlm.nih.gov/PMC7029813 https://doi.org/10.1016/s2352-3026%2818%2930030-9
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/43133 https://portal.issn.org/resource/ISSN/2352-3026
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial
discusses	http://id.nlm.nih.gov/mesh/M0020790 http://id.nlm.nih.gov/mesh/M0018357 http://id.nlm.nih.gov/mesh/M0579638
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D015451Q000188 http://id.nlm.nih.gov/mesh/D008228Q000188 http://id.nlm.nih.gov/mesh/D013449Q000627 http://id.nlm.nih.gov/mesh/D011810Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D015331 http://id.nlm.nih.gov/mesh/D008228Q000473 http://id.nlm.nih.gov/mesh/D015451Q000473 http://id.nlm.nih.gov/mesh/D013449Q000494 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D011810Q000494
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9720 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7353 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9859 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16123056 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10603 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c7be83279551b50c0e81dc2dbfe3c5d8 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d0bb789479d34dbc0811f92fc2bc5049 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7732 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7507 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6910 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID49867926 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8389 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8388 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8390 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8911 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9408

Showing number of triples: 1 to 77 of 77.